HDCN Abstract:  ASN Annual Meeting 2020 -- Digital Meeting  

Jayne DR, Merkel PA, Yue H, et al.

Complement C5a Receptor Inhibitor Avacopan Improves Renal Function in ANCA Vasculitis

ASN Annual Meeting 2020 -- Digital Meeting
J Am Soc Nephrol (Oct) 31:53A 2020

BACKGROUND

Renal impairment is common in anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The resulting chronic kidney disease and exacerbation of the toxicity risks of high dose or prolonged glucocorticoid use, a mainstay of ANCA treatment, are major consequences. Avacopan was tested for efficacy and effects on renal function compared to standard prednisone therapy in a randomized double-blind Phase 3 trial in ANCA vasculitis.

METHODS

Subjects randomized 1:1 received either prednisone (60 mg tapered to 0 over 20 weeks) or avacopan (30 mg twice daily for 52 weeks), combined with either cyclophosphamide (CYC) followed by azathioprine, or rituximab (RTX). Primary endpoints: Disease remission at week 26 and sustained remission at week 52. Changes in urinary albumin to creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) were also assessed.

RESULTS

330 subjects were treated: 166 to avacopan and 164 to prednisone treatment groups. Avacopan remission at week 26 was 72.3% vs. 70.1%, for prednisone (P<0.0001 for non-inferiority); avacopan was superior to prednisone for sustained remission (week 52, 65.7%, avacopan vs. 54.9%, prednisone, P=0.0066).
81% percent of subjects had renal disease. UACR decreased more rapidly with avacopan than prednisone: week 4 avacopan was 40% below baseline vs. no change for prednisone (P<0.0001). Baseline to week 52 eGFR (mL/min/1.73 m2) improvement: avacopan eGFR +7.3 vs. prednisone +4.1 (P=0.029). In subjects with baseline eGFR <30: mean eGFR improved 67% more with avacopan than prednisone to week 52: avacopan eGFR +13.7 vs. prednisone +8.2 (P=0.01).

CONCLUSION

Treatment with avacopan for ANCA vasculitis compared with standard glucocorticoid therapy (both combined with either CYC or RTX) is as effective for remission induction at 26 weeks, and superior to prednisone for sustained remission after 52 weeks. Avacopan led to faster falls in UACR and greater recovery in eGFR when compared to standard prednisone therapy. These findings have important implications for the long term health of AAV patients through better overall disease control, reduced prednisone exposure and reduced severity of chronic kidney disease.

c Copyright 2020 -2021 American Society of Nephrology. Reproduced with permission.
All ASN abstracts from the 2020 Annual Meeting are available at this link and also are archived in .pdf form at ASN-Online.org

Disclaimer: Abstracts often have errors, both typographical and otherwise. This posting is an electronic translation of submitted abstracts which has not been verified against the original submitted abstract nor with the authors for accuracy. As a result, there may be errors, especially with regard to drug doses, but not limited to these. Abstracts undergo only limited review, and data often are changed as a result of the peer review process, so their reliability is less than manuscripts published in peer-reviewed journals. In using these summaries, you are agreeing that you are aware of these limitations.

The materials are provided on an as-is basis without any warranty of any kind, either express or implied. In addition to errors, the information presented may be incomplete or outdated. The information contained is not intended nor recommended as a substitute for professional medical advice. You are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each device to be used or drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other health care professional, relying on independent experience and knowledge of the patient, to determine drug, disease, and the best treatment for the patient.

To the fullest extent permitted by law, HDCN, ASN and their affiliates and suppliers disclaim all warranties, express or implied, including, but not limited to, any warranty of merchantability, non- infringement or fitness for a particular purpose.

In no event shall HDCN, ASN, or their affiliates or suppliers be liable for any damages whatsoever (including, but not limited to, direct, indirect, incidental, consequential, punitive or exemplary damages, or any damages for loss of profits, use, data, goodwill or other intangibles) arising from or in any way relating to these terms, the materials, or any information, goods or services obtained from or referred to in the materials, whether based on warranty, contract, tort (including, but not limited to, negligence), or any other legal theory, and whether or not any or all of the limited entities is advised of the possibility of such damages.